Previous 10 | Next 10 |
VANCOUVER – FlyOnWallStreet – New clinical trials based out of Australia are exploring the therapeutic benefits of psychedelics (which are currently illegal substances), in what’s been described as a “ paradigm shifter ” for psychiatry. In particul...
NetworkNewsWire Editorial Coverage : The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-tre...
Evercore ISI has set up its list of key catalysts for the rest of 2021 in the biotechnology sector - including early-stage data readouts as well as some important legal and regulatory updates ahead for particular companies. Along the way it tees up its rule of thumb on biotech catalysts: "Alw...
Innovation in the pharmaceutical industry has never been more exciting than it is right now, and there are some excellent companies that could be big winners for patient investors. In this Fool Live clip, recorded on Sept. 15 , Fool.com contributor Jason Hall explains to Senior Anal...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2021 – The global need for effective mental health treatment has led to the growing push for the legalization of psychedelic therapies, pushing the market into the mainstre...
Psychedelics, like ketamine could be key to revolutionizing mental health. In fact, according to medical university, Karolinska Institutet, “In a new study, researchers at Karolinska Institutet have further investigated the molecular mechanisms underlying ketamine's antidepressant ef...
London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming investor conferences as f...
COMPASS IPO'd in September last year, at $17 per share - by December, shares had hit $59. Current market cap is $1.4bn. The company has developed a proprietary formulation of Psilocybin - the hallucinogenic found in magic mushrooms. Its approach is unique, with patients undergoing...
Psychedelics could change the way we address mental health issues all over the world, creating multi-billion-dollar opportunities along the way. All as such drugs prove to be a major game changer for millions of people all over the world. Countless studies are already proving such treatment...
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...